Lonza & Thermo Fisher Scientific -Notable Market Players in Biopharmaceuticals Contract Manufacturing Market
Biopharmaceuticals contract manufacturing refers to pharmaceutical companies outsourcing the development and manufacturing of drugs. CMOs have become a known name among pharmaceutical companies due to their cost effective services. The CMOs offer a wide range of services including research and development, analytical services and final dosage preparation and packaging. Moreover, growing biopharma industry is offering lucrative opportunities for the growth of the market.
Market leaders operating in the market have undertaken various organic growth strategies in the biopharmaceuticals contract manufacturing market. The biopharmaceuticals contract manufacturing market majorly consists of the players such as Lonza Group AG, Boehringer Ingelheim International GmbH, Inno Biologics Ventures Sdn Bhd, Thermo Fisher Scientific, AbbVie Inc., Wuxi Biologics, General Electric, Samsung Biologics, Merck KGaA, Ajinomoto Co., Inc and others. Several organic approaches, such as product launches, and expansion in the biopharmaceuticals contract manufacturing market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the biopharmaceuticals contract manufacturing market:
|
Year |
News |
|
Nov-19 |
The company WuXi Biologics through its subsidiary WuXi Vaccines that is involved in the Contract Development and Manufacturing Organization (CDMO) business has invested about 240 million USD for the new vaccine manufacturing facility located in Ireland. This development has helped the company to expand its business in the region. |
| Jan-19 |
WUXI BIOLOGICS has initiated the process to expand its commercial manufacturing facilities for biologics in China. As a part of the expansion the company has installed additional 2x 2.000L single use bioreactor and all the required utility and infrastructure settings to support the GMP operations of manufacturing lines. |
